Recurring Weakness in Rhabdomyolysis Following Pfizer–BioNTech Coronavirus Disease 2019 mRNA Vaccination

Rhabdomyolysis is a well-known clinical syndrome of muscle injury. Rhabdomyolysis following coronavirus disease 2019 (COVID-19) vaccination has recently been reported. The patients’ weakness gradually subsided and did not recur. Rhabdomyolysis associated with COVID-19 vaccination has not been assess...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-06, Vol.10 (6), p.935
Main Authors: Kimura, Motoya, Niwa, Jun-Ichi, Doyu, Manabu
Format: Article
Language:English
Subjects:
Antibodies
Blood
Case Report
Coronaviruses
COVID-19
COVID-19 vaccination
COVID-19 vaccines
Creatine
Creatine kinase
Cytokines
Disease
Electrolytes
Hospitalization
Immunization
Influenza
Intravenous administration
Kinases
Laboratories
Magnetic resonance imaging
Medical research
mRNA
mRNA vaccine
Muscles
Myalgia
Patients
Rhabdomyolysis
Signs and symptoms
Tetanus
Tumor necrosis factor-TNF
Vaccination
Vaccines
Viral diseases
weakness
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rhabdomyolysis is a well-known clinical syndrome of muscle injury. Rhabdomyolysis following coronavirus disease 2019 (COVID-19) vaccination has recently been reported. The patients’ weakness gradually subsided and did not recur. Rhabdomyolysis associated with COVID-19 vaccination has not been assessed by repeated magnetic resonance imaging (MRI) within a short time. We report a rare case of an older woman who developed recurring weakness with rhabdomyolysis after COVID-19 vaccination. A 76-year-old woman presented with myalgia 2 days after receiving a third dose of the COVID-19 vaccine. A physical examination showed weakness of the bilateral iliopsoas muscles. Her creatine kinase concentration was 9816 U/L. MRI showed hyperintensity of multiple limb muscles. She was treated with intravenous normal saline. Her symptoms disappeared within 3 days. However, MRI on day 4 of hospitalization showed exacerbation of the hyperintensity in the left upper limb muscles. On day 5 of hospitalization, weakness of the left supraspinatus and deltoid muscles appeared. MRI on day 8 of hospitalization showed attenuation of the hyperintensity in all muscles. Her weakness and elevated creatine kinase concentration disappeared by day 10. Repeated MRI over a short time may be useful to predict potential weakness and monitor the course of COVID-19 vaccine-induced rhabdomyolysis.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10060935